UNIVERSITAS
GADJAH MADA
Pengaruh Skizofrenia Terhadap Profil Darah Pasien: Systematic Review
ANDREA RADYAPUTRI, Dr. dr. Ronny Tri Wirasto, Sp. KJ; dr. Andrian Fajar Kusumadewi, M.Sc., Sp.KJ; dr. Jajar Se
Universitas Gadjah Mada, 2020 | Diunduh dari http://etd.repository.ugm.ac.id/

DAFTAR PUSTAKA

Akpinar, A. and Salis, O., 2012. Evaluation of the Incidence of Leukopenia and Agranulocytosis in Patients Receiving Combined Clozapine and Other Antipsychotics. *Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology*, 22(4), pp.313-319.

Al-chalabi Basil M., Thanoon, I. A. J., & Ahmed, F. A., 2009. Potential Effect of Olanzapine on Total Antioxidant Status and Lipid Peroxidation in Schizophrenic Patients. *Neuropsychobiology*, 59(1), pp.8–11.

Al Qahtani, S., 2018. Review Article: Drug-induced megaloblastic, aplastic, and hemolytic anemias: current concepts of pathophysiology and treatment. *Int J Clin Exp Med*, 11(6), pp. 5502-5503

Al-Amin, M., Uddin, M., Reza, H., 2013. Effects of Antipsychotics on the Inflammatory Response System of Patients with Schizophrenia in Peripheral Blood Mononuclear Cell Cultures. *Clinical Psychopharmacology and Neuroscience,* 11(3), pp. 144-151

Ali, I., Abu-Taha, A., Zahran, H., 2017. Prevalence of Anemia among Schizophrenic Patients in Palestine. *Palestinian Medical and Pharmaceutical Journal* (PMPJ), 2(2), pp. 70-74

Altamura, C., Fagiolini, A., Galderisi, S., Rocca, P. and Rossi, A., 2014. Schizophrenia today: Epidemiology, diagnosis, course and models of care. *Italian Journal of Psychopathology*, 20(3), pp. 223-243.

American Psychiatric Association, 2013. *Diagnostic and statistical manual of mental disorders.* 5th ed. Arlington, VA: Author.

Andrès, E. and Mourot-Cottet, R., 2018. Idiosyncratic Drug-Induced Severe Neutropenia and Agranulocytosis: State of the Art. *Hematology - Latest Research and Clinical Advances.*

Andrès, E., Zimmer, J., Mecili, M., Weitten, T., Alt, M. and Maloisel, F., 2011. Clinical presentation and management of drug-induced agranulocytosis. *Expert Review of Hematology*, 4(2), pp.143-151.

Arsova, S., Bajraktarov, S., Barbov, I. and Hadzihamza, K., 2014. Patients with Schizophrenia and Self-Care. *Open Access Macedonian Journal of Medical Sciences*, 2(2), p.289.

Balcioglu, Y., Guvenc, H., Ozgen, G., Berkol, T., Kalelioglu, T. and Oncu, F., 2016. Propensity of Anemia of Chronic Disease to be a Promising Evidence for Chronic Inflammatory Status in Schizophrenia. In: *The European College of Neuropsychopharmacology Congress*. Vienna: The European College of Neuropsychopharmacology Congress.

Bobes-Bascarán, M., García-Portilla, M., Martínez, P., García-Alvarez, L., Menéndez-Miranda, I., Al-Halabí, S., Bascarán, M. and Bobes, J., 2016. A Review of Quality-of-Life Assessment Measures in Schizophrenia: Limitations and Future Developments. *Beyond Assessment of Quality of Life in Schizophrenia*, pp.65-77.

Borges, S., Gayer-Anderson, C., & Mondelli, V., 2013. A systematic review of the activity of the hypothalamic–pituitary–adrenal axis in first episode psychosis. *Psychoneuroendocrinology*, 38(5), pp.603–611.

Chen, C., Lin, T., Chen, T., Chen, V., Lin, N., Shao, W. and Lu, M., 2011. A prospective study of glucose homeostasis in quetiapine-treated schizophrenic patients by using the intravenous glucose tolerance test. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, 35(4), pp.965-969.

Chokhawala, K. and Stevens, L., 2020. *Antipsychotic Medications*. [online] ncbi.nlm.nih.gov. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK519503/> [Accessed 29 February 2020].

Chue P, Mandel FS, Therrien F, 2014. The effect of ziprasidone on metabolic syndrome risk factors in subjects with schizophrenia: a 1 year, open-label, prospective study. *Curr Med Res Opin,* 30(6), pp. 997-1005

Crismon, L., Argo T.R., and Buckley P.F., 2014. Schizophrenia. In: J.T. DiPiro, R.L. Talbert, G.C. Yee, G.R. Matzke, B.G. Wells, L.M. Posey eds. *Pharmacotherapy: A Pathophysiologic Approach*. 9th ed. New York: McGraw-Hill, pp.1019–1046.

Curto, M., Comparelli, A., Ciavarella, G., Gasperoni, C., Lionetto, L., Corigliano, V., Uccellini, A., Mancinelli, I., Ferracuti, S., Girardi, P. and Baldessarini, R., 2015. Impairment of left ventricular function early in treatment with clozapine. *International Clinical Psychopharmacology*, 30(5), pp.282-289.

Daniel, J.S. and Gross, T., 2016. Managing clozapine-induced neutropenia and agranulocytosis. *Savvy Psychopharmacology*, 15(12), pp.51-53.

De Berardis, D., Rapini, G., Olivieri, L., Di Nicola, D., Tomasetti, C., Valchera, A., Fornaro, M., Di Fabio, F., Perna, G., Di Nicola, M., Serafini, G., Carano, A., Pompili, M., Vellante, F., Orsolini, L, Martinotti, G., Di Giannantonio, M., 2018. Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine. *Therapeutic Advances in Drug Safety,* 9(5), pp. 237–256.

del Campo, A., Bustos, C., Mascayano, C., Acuña-Castillo, C., Troncoso, R. and Rojo, L., 2018. Metabolic Syndrome and Antipsychotics: The Role of Mitochondrial Fission/Fusion Imbalance. *Frontiers in Endocrinology*, 9.

Ehrlich, D. and Humpel, C., 2012. Platelets in psychiatric disorders. *World Journal of Psychiatry*, 2(6), p.91.

Elvira, S.D. and Hadisukanto, G., 2013. *Buku Ajar Psikiatri*. Jakarta: Badan Penerbit Fakultas Kedokteran Universitas Indonesia.

Emsley R, Asmal L, Chiliza B, du Plessis S, Carr J, Kidd M, Malhotra AK, Vink M, Kahn RS, 2015. Changes in brain regions associated with food-intake regulation, body mass and metabolic profiles during acute antipsychotic treatment in first-episode schizophrenia. *Psychiatry Res,* 233(2), pp.186-193

Fatani, B., Aldawod, R. and Alhawaj, F., 2017. Schizophrenia : Etiology, Pathophysiology and Management : A Review. *The Egyptian Journal of Hospital Medicine*, 69(6), pp.2640-2646.

Faye, A., Kirpekar, V., Bhave, S., Tadke, R. and Gawande, S., 2019. Lurasidone-induced anemia: Is there a need for hematological monitoring?. *Indian Journal of Pharmacology*, 51(4), p.276.

Feng, Z., Zhang, Y., You, X., Zhang, W., Ma, Y., Long, Q., Liu, Z., Hao, W., Zeng, Y., Teng, Z., 2020. Effects of risperidone on blood levels of interleukin-6 in schizophrenia: a meta-analysis. *Medicine* 99(15), e19694.

Fischbach, F. and B. Dunning III, M., 2015. *A Manual Of Laboratory And Diagnostic Test*. 9th ed. China: Lippincott Williams & Wilkins, pp.67-83.

Furukawa, T., Levine, S., Tanaka, S., Goldberg, Y., Samara, M., Davis, J., Cipriani, A. and Leucht, S., 2014. Initial Severity of Schizophrenia and Efficacy of Antipsychotics. *JAMA Psychiatry*, 72(1), p.14.

Giesbrecht, C., O'Rourke, N., Leonova, O., Strehlau, V., Paquet, K., Vila-Rodriguez, F., Panenka, W., MacEwan, G., Smith, G., Thornton, A. and

Honer, W., 2016. The Positive and Negative Syndrome Scale (PANSS): A Three-Factor Model of Psychopathology in Marginally Housed Persons with Substance Dependence and Psychiatric Illness. *PLOS ONE*, 11(3), p.e0151648.

Goetz, R. and Miller, B., 2019. Meta-analysis of ghrelin alterations in schizophrenia: Effects of olanzapine. *Schizophrenia Research*, 206, pp.21-26.

Green, M., Matheson, S., Shepherd, A., Weickert, C. and Carr, V., 2010. Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. *Molecular Psychiatry*, 16(9), pp.960-972.

Grover, S., Kulhara, P., Chakrabarti, S. and Malhotra, N., 2013. Metabolic syndrome in schizophrenia. *Indian Journal of Psychological Medicine*, 35(3), p.227.

Hany M, Rehman B, Azhar Y, et al. Schizophrenia. [Updated 2020 Apr 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK539864/

Hayden, J., van der Windt, D., Cartwright, J., Côté, P. and Bombardier, C., 2013. Assessing Bias in Studies of Prognostic Factors. *Annals of Internal Medicine*, 158(4), p.280.

Higgins, J., Altman, D., Gotzsche, P., Juni, P., Moher, D., Oxman, A., Savovic, J., Schulz, K., Weeks, L. and Sterne, J., 2011. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ*, 343(oct18 2), pp.d5928-d5928.

Hoirisch-Clapauch, S., Amaral, O., Mezzasalma, M., Panizzutti, R. and Nardi, A., 2016. Dysfunction in the coagulation system and schizophrenia. *Translational Psychiatry*, 6(1), pp.e704-e704.

Howes, O. D., & McCutcheon, R, 2017. Inflammation and the neural diathesis-stress hypothesis of schizophrenia: a reconceptualization. *Translational Psychiatry*, 7(2), e1024–e1024.

Huang YC, Lin PY, Lee Y, Hung CF, Hsu ST, Wu CC, Wang LJ, 2018. Serum levels of β-hydroxybutyrate and pyruvate, metabolic changes and cognitive function in patients with schizophrenia during antipsychotic treatment: a preliminary study. *Neuropsychiatr Dis Treat,*14, pp.799-808

Ingimarsson, O., MacCabe, J., Haraldsson, M., Jónsdóttir, H. and Sigurdsson, E., 2016. Neutropenia and agranulocytosis during treatment of schizophrenia with clozapine versus other antipsychotics: an observational study in Iceland. *BMC Psychiatry*, 16(1).

Jombo, H. and Ekwere, T., 2018. A Cross-Sectional Study of the Impact of Antipsychotic Medications on the Hematological Profile of Patients with Schizophrenia in a Tertiary Health Facility in Uyo, South-South, Nigeria. *International Neuropsychiatric Disease Journal*, 11(2), pp.1-9.

Kementerian Kesehatan Republik Indonesia, 2016. Peran Keluarga Dukung Kesehatan Jiwa Masyarakat. [online] Available at: <https://www.kemkes.go.id/article/print/16100700005/peran-keluarga-dukung-kesehatan-jiwa-masyarakat.html> [Accessed 21 January 2020].

Khandaker, G. M., Cousins, L., Deakin, J., Lennox, B. R., Yolken, R., & Jones, P. B, 2015. Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. *The Lancet Psychiatry,* 2(3), pp. 258–270.

Korkmaz, S., Yildiz, S., Korucu, B., Gundogan, B., Sunbul, Z., Korkmaz, H., Atmaca, M., 2015. Frequency of anemia in chronic psychiatry patients. *Neuropsychiatric Disease and Treatment,* 11, pp. 2737–2741

Kornetova EG, Kornetov AN, Mednova IA, Dubrovskaya VV, Boiko AS, Bokhan NA, Loonen AJM, Ivanova SA, 2019. Changes in Body Fat and Related Biochemical Parameters Associated With Atypical Antipsychotic Drug Treatment in Schizophrenia Patients With or Without Metabolic Syndrome. *Front Psychiatry,* 10

Kroken, R., Sommer, I., Steen, V., Dieset, I. and Johnsen, E., 2019. Constructing the Immune Signature of Schizophrenia for Clinical Use and Research; An Integrative Review Translating Descriptives Into Diagnostics. *Frontiers in Psychiatry*, 9.

Kubota, Y. and Ezekiel Wong, T., 2018. Severe Drug-Induced Agranulocytosis Successfully Treated with Recombinant Human Granulocyte Colony-Stimulating Factor. *Case Reports in Medicine*, 2018, pp.1-3.

Larson, M., Walker, E. and Compton, M., 2010. Early signs, diagnosis and therapeutics of the prodromal phase of schizophrenia and related psychotic disorders. *Expert Review of Neurotherapeutics*, 10(8), pp.1347-1359.

Liu, J.Y., Chen, H.Y., Lin, J.J., Lu, M.K., Tan, H.P., Jang, F.L., and Lin, S.H., 2020. Alterations of plasma cytokine biomarkers for identifying age at onset of schizophrenia with neurological soft signs. *Int J Med Sci,* 17(2), pp.255-262

Lundblad, W., Azzam, P., Gopalan, P., Ross, C. and PharmD, 2015. Medical management of patients on clozapine: A guide for internists. *Journal of Hospital Medicine*, 10(8), pp.537-543.

Mahant, S., Mahant, P. and Shobhane, U., 2015. How to approach drug-induced agranulocytosis in ICU. *The Egyptian Journal of Haematology*, 40(3), p.109.

Malhotra, N., Grover, S., Chakrabarti, S., & Kulhara, P., 2013. Metabolic syndrome in schizophrenia. *Indian journal of psychological medicine*, *35*(3), pp. 227–240

Maslim, R., 2014. *Panduan Praktis Penggunaan Klinis Obat Psikotropik (Psychotropic Medication*). 4th ed. Jakarta: Bagian Ilmu Kedokteran Jiwa FK-Unika Atmajaya, Kompleks RS Atmajaya.

Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., The PRISMA Group, 2009. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Med* 6(6), e1000097

Muench, J. and Hamer, A., 2010. Adverse Effects of Antipsychotic Medications. *American Family Physician*, 81(5).

Müller, N. and Schwarz, M.J., 2010. Immune System and Schizophrenia. *Curr Immunol Rev,* 6(3), pp.213-220.

Na, K., Kim, W., Jung, H., Ryu, S., Min, K., Park, K., Kim, Y., Yoon, J., Ahn, Y. and Kim, C., 2012. Relationship between inflammation and metabolic syndrome following treatment with paliperidone for schizophrenia. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, 39(2), pp.295-300.

Najjar, S., Pearlman, D.M., Alper, K., Najjar, A. and Devinsky, O., 2013. Neuroinflammation and psychiatric illness. *Journal of Neuroinflammation,* 10(43), pp.1-24

Nederlof, M., Frederix, G., Stoker, L., van Solinge, W., Egberts, T. and Heerdink, E., 2016. Patient monitoring: the hidden costs of treatment with antipsychotics. *British Journal of Clinical Pharmacology*, 82(2), pp.570-572.

Nyboe, L., Vestergaard, C., Moeller, M., Lund, H. and Videbech, P., 2015. Metabolic syndrome and aerobic fitness in patients with first-episode schizophrenia, including a 1-year follow-up. *Schizophrenia Research*, 168(1-2), pp.381-387.

Ojong, M. and Allen, S., 2013. Management and prevention of agranulocytosis in patients receiving clozapine. *Mental Health Clinician*, 3(3), pp.139-143.

Opler, M., Yavorsky, C., Daniel, D., 2017. Positive and Negative Syndrome Scale (PANSS) Training: Challenges, Solutions, and Future Directions. *INNOVATIONS IN CLINICAL NEUROSCIENCE,* 14(11-12), pp. 77-81

Patel, K.R., Cherian, J., Gohil, K., and Atkinson, D., 2014. Schizophrenia: Overview and Treatment Options. *P&T,* 39(9), pp.638-644.

Perkovic, M., Erjavec, G., Strac, D., Uzun, S., Kozumplik, O. and Pivac, N., 2017. Theranostic Biomarkers for Schizophrenia. *International Journal of Molecular Sciences*, 18(4), p.733.

Pillinger, T., McCutcheon, R., Vano, L., Mizuno, Y., Arumuham, A., Hindley, G., Beck, K., Natesan, S., Efthimiou, O., Cipriani, A. and Howes, O., 2020. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. *The Lancet Psychiatry*, 7(1), pp.64-77.

Polho, G., De-Paula, V., Cardillo, G., dos Santos, B. and Kerr, D., 2015. Leukocyte telomere length in patients with schizophrenia: A meta-analysis. *Schizophrenia Research*, 165(2-3), pp.195-200.

Reus, V., 2015. Mental Disorders. In: D. Kasper, S. Hauser, J. Jameson, A. Fauci, D. Longo and J. Loscalzo, ed., *Harrison's Principles of Internal Medicine*, 19th ed. McGraw-Hill Education, pp.2720-2723.

Review Manager (RevMan) [Computer program]. Version 5.4, The Cochrane Collaboration, 2020.

Richards, G.R. and Onakpoya, I.J., 2019. Catalogue of Bias: Reporting biases. In: Catalog Of Bias 2019: www.catalogueofbiases.org/reportingbiases

Riskesdas, 2013. *Prevalensi gangguan jiwa berat DIY tertinggi di Indonesia*. Jakarta: Riset Kesehatan Dasar Kementerian Kesehatan Republik Indonesia.

UNIVERSITAS
GADJAH MADA
Pengaruh Skizofrenia Terhadap Profil Darah Pasien: Systematic Review
ANDREA RADYAPUTRI, Dr. dr. Ronny Tri Wirasto, Sp. KJ; dr. Andrian Fajar Kusumadewi, M.Sc., Sp.KJ; dr. Jajar Se
Universitas Gadjah Mada, 2020 | Diunduh dari http://etd.repository.ugm.ac.id/

Rochlani, Y., Pothineni, N., Kovelamudi, S. and Mehta, J., 2017. Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. *Therapeutic Advances in Cardiovascular Disease*, 11(8), pp.215-225.

Romeo, B., Brunet-Lecomte, M., Martelli, C. and Benyamina, A., 2018. Kinetics of Cytokine Levels during Antipsychotic Treatment in Schizophrenia: A Meta-Analysis. *International Journal of Neuropsychopharmacology*, 21(9), pp.828-836.

Sadock, B.J., Sadock,V.A., and Ruiz, P., 2015. *Synopsis of psychiatry: Behavioral Sciences Clinical Psychiatry.* 11th ed. New York: Wolters Kluwer.

Salviato Balbão M, Cecílio Hallak JE, Arcoverde Nunes E, Homem de Mello M, Triffoni-Melo Ade T, Ferreira FI, Chaves C, Durão AM, Ramos AP, de Souza Crippa JA, Queiroz RH, 2014. Olanzapine, weight change and metabolic effects: a naturalistic 12-month follow up. *Ther Adv Psychopharmacol,* 4(1), pp.30-36

Schwarz, E., Guest, P. C., Rahmoune, H., Harris, L. W., Wang, L., Leweke, F. M., Rothermundt, M., Bogerts, B., Koethe, D., Kranaster, L., Ohrmann, P., Suslow, T., McAllister, G., Spain, M., Barnes, A., van Beveren, N.J.M., Baron-Cohen, S., Steiner, J., Torrey, F.E., Yolken, R.H., Bahn, S., 2011. Identification of a biological signature for schizophrenia in serum. *Molecular Psychiatry*, 17(5), pp.494–502.

Shakeri, J., Karimi, K., Farnia, V., Golshani, S. and Alikhani, M., 2016. revalence of Metabolic Syndrome in Patients with Schizophrenia Referred to Farabi Hospital, Kermanshah, Iran. *Oman Medical Journal*, 31(4), pp.270-275.

Shea, B.J., Reeves, B.C., Wells, G., Thuku, M., Hamel, C., Moran, J., Moher, D., Tugwell, P., Welch, V., Kristjansson, E., Henry, D.A., 2017. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. *BMJ,* 21(358), j4008.

Singh, M., Solanki, R.K., Bagaria, B., Swami, M.K., 2015. Hypothalamic-Pituitary-Adrenal (HPA) Axis Functioning among Patients with Schizophrenia: A Cross Sectional Comparative Study. *Journal of Psychiatry*, 18(1), pp.5-6

Sood, S., 2017. Neutropenia with Multiple Antipsychotics Including Dose Dependent Neutropenia with Lurasidone. *Clinical Psychopharmacology and Neuroscience*, 15(4), pp.413-415.

Sterne, J.A.C., Higgins, J.P.T., Elbers, R.G., Reeves, B.C. and the development group for ROBINS-I, 2016. Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I): detailed guidance. *BMJ,* 355, i4919

Stip E, Lungu OV, Anselmo K, Letourneau G, Mendrek A, Stip B, Lipp O, Lalonde P, Bentaleb LA, 2012. Neural changes associated with appetite information processing in schizophrenic patients after 16 weeks of olanzapine treatment. *Transl Psychiatry,* 2(6), p.e128.

Subbanna, M., Shivakumar, V., Venugopal, D., Narayanaswamy, J., Berk, M., Varambally, S., Venkatasubramanian, G. and Debnath, M., 2019. Impact of antipsychotic medication on IL-6/ STAT3 signaling axis in peripheral blood mononuclear cells of drug-naive schizophrenia patients. *Psychiatry and Clinical Neurosciences*, 74(1), pp.64-69.

Tomasik, J., Schwarz, E., Guest, P. and Bahn, S., 2012. Blood test for schizophrenia. *European Archives of Psychiatry and Clinical Neuroscience*, 262(S2), pp.79-83.

Tomasik, J., Schwarz, E., Lago, S., Rothermundt, M., Leweke, F., van Beveren, N., Guest, P., Rahmoune, H., Steiner, J. and Bahn, S., 2016. Pretreatment levels of the fatty acid handling proteins H-FABP and CD36 predict response to olanzapine in recent-onset schizophrenia patients. *Brain, Behavior, and Immunity*, 52, pp.178-186.

Turangan, D., Loebis, B., Husada, S. and Nasution, N., 2019. Differences of Fasting Blood Glucose Level in People with Schizophrenia between Before and After Getting Aripiprazole Treatment. *Open Access Macedonian Journal of Medical Sciences*, 7(16), pp.2607-2611.

Voulgari, C., Giannas, R., Paterakis, G., Kanellou, A., Anagnostopoulos, N. and Pagoni, S., 2015. Clozapine-Induced Late Agranulocytosis and Severe Neutropenia Complicated with Streptococcus pneumonia, Venous Thromboembolism, and Allergic Vasculitis in Treatment-Resistant Female Psychosis. *Case Reports in Medicine*, 2015, pp.1-7.

Wasti, A., Zahid, S., Ahmed, N., 2013. Antipsychotic drugs induced iron deficiency anemia in schizophrenic patients. *International Journal of Advanced Research,* (1), pp. 111-118.

Wójciak, P., Remlinger-Molenda, A., Rybakowski, J., 2016. Stages of the clinical course of schizophrenia– staging concept. *Psychiatr. Pol.,* 50(4), pp. 717-730

UNIVERSITAS
GADJAH MADA
Pengaruh Skizofrenia Terhadap Profil Darah Pasien: Systematic Review
ANDREA RADYAPUTRI, Dr. dr. Ronny Tri Wirasto, Sp. KJ; dr. Andrian Fajar Kusumadewi, M.Sc., Sp.KJ; dr. Jajar Se
Universitas Gadjah Mada, 2020 | Diunduh dari http://etd.repository.ugm.ac.id/

Wolff, R., Moons, K., Riley, R., Whiting, P., Westwood, M., Collins, G., Reitsma, J., Kleijnen, J. and Mallett, S., 2019. PROBAST: A Tool to Assess the Risk of Bias and Applicability of Prediction Model Studies. *Annals of Internal Medicine*, 170(1), p.51.

Xiao, W., Zhan, Q., Ye, F., Tang, X., Li, J., Dong, H., Sha, W. and Zhang, X., 2018. Elevated serum vascular endothelial growth factor in treatment-resistant schizophrenia treated with electroconvulsive therapy: Positive association with therapeutic effects. *The World Journal of Biological Psychiatry*, 20(2), pp.150-158.

Xiong, Z., Cheng, M., Zhu, P., Huang, S., Guo, J., Zhang, W., Zhou, H., Shu, Y. and Li, Q., 2019. Association of blood cell counts with the risk of olanzapine- or clozapine-induced dyslipidemia in Chinese schizophrenia patients. *Human Psychopharmacology: Clinical and Experimental*.

Yuan, X., Zhang, P., Wang, Y., Liu, Y., Li, X., Kumar, B., Hei, G., Lv, L., Huang, X., Fan, X. and Song, X., 2018. Changes in metabolism and microbiota after 24-week risperidone treatment in drug naïve, normal weight patients with first episode schizophrenia. *Schizophrenia Research*, 201, pp.299-306.

Yusuf, A., Endang Nihayati, H., and Eka Kurniawan, K., 2017. MODELING PARTICIPANT TOWARD SELF-CARE DEFICIT ON SCHIZOPHRENIC CLIENTS. *Jurnal Ners,* 12(1), pp.41-48

Zahnia, S. and Wulan Sumekar, D., 2016. Kajian Epidemiologis Skizofrenia. *MAJORITY*, 5(4), pp.160-165

Zeier, K., Connell, R., Resch, W., Thomas, C.J., 2013. Recommendations for lab monitoring of atypical antipsychotics. *Savvy Psychopharmacology*, 12(9), pp. 51-53

Zhang, X., Zhou, D., Shen, Y., Zhang, P., Zhang, W., Liang, J., Chen, D., Xiu, M., Kosten, T. and Kosten, T., 2012. Effects of risperidone and haloperidol on superoxide dismutase and nitric oxide in schizophrenia. *Neuropharmacology*, 62(5-6), pp.1928-1934.

Zhang, Y., Liu, Y., Su, Y., You, Y., Ma, Y., Yang, G., Song, Y., Liu, X., Wang, M., Zhang, L. and Kou, C., 2017. The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis. *BMC Psychiatry*, 17(1).

UNIVERSITAS
GADJAH MADA
Pengaruh Skizofrenia Terhadap Profil Darah Pasien: Systematic Review
ANDREA RADYAPUTRI, Dr. dr. Ronny Tri Wirasto, Sp. KJ; dr. Andrian Fajar Kusumadewi, M.Sc., Sp.KJ; dr. Jajar Se
Universitas Gadjah Mada, 2020 | Diunduh dari http://etd.repository.ugm.ac.id/

Zhran, H., 2013. *Blood Profile Of Schizophrenic Clients In Northern Palestine*. An-Najah National University Faculty of Graduate Studies.